<DOC>
	<DOC>NCT00955045</DOC>
	<brief_summary>The primary objective of this study was to establish the long-term tolerability and safety of istradefylline treatment in subjects with Parkinson's disease treated with levodopa/carbidopa. In addition, treatment response and maintenance of response were assessed.</brief_summary>
	<brief_title>A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Istradefylline</mesh_term>
	<criteria>Eligible subjects were: male or female at least 30 years of age had completed participation in a prior doubleblind istradefylline trial met United Kingdom's Parkinson's Disease Society (UKPDS) brain bank criteria (Step 1 and Step 2) for Parkinson's disease and the severity of the Parkinson's disease was defined as Stages 24 on the Modified Hoehn and Yahr Scale while in the OFF state had been treated with levodopa for at least 1 year had been on a stable Parkinson's disease regimen within normal therapeutic ranges including levodopa for at least 4 weeks before Baseline were currently taking at least 4 doses of levodopa per day (3 doses per day if at least 2 doses contained slowrelease formulation) had predictable endofdose wearingoff</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>long-term tolerability and safety</keyword>
	<keyword>istradefylline treatment</keyword>
	<keyword>levodopa/carbidopa</keyword>
</DOC>